Survodutide
Reviewed by Fat Man in the Arena · Updated March 2026
Key Takeaway
Survodutide is a dual GLP-1/glucagon receptor agonist developed by Boehringer Ingelheim, currently in Phase 3 trials for obesity and metabolic liver disease.
How it works
Activates both GLP-1 and glucagon receptors. The glucagon component increases energy expenditure and hepatic fat oxidation while GLP-1 reduces appetite.
Benefits
- Up to 19% weight loss in Phase 2
- Significant liver fat reduction
- Potential MASH treatment
Side effects
- Nausea
- Diarrhea
- Vomiting
- Similar to other GLP-1 agonists
Dosing protocol
Typical Dose
0.6 mg to 4.8 mg weekly
Frequency
Once weekly
Phase 3 dosing not yet finalized.
Key research
Survodutide for Obesity (Phase 2)
New England Journal of Medicine (2024) — PubMed
19.2% body weight loss at highest dose over 46 weeks.
Compare Survodutide
Related peptides
Weekly peptide research updates
New studies, GLP-1 news, protocol insights, and weight loss data — delivered every week. Free. No spam.
Medical Disclaimer: This content is for informational and educational purposes only. It is not intended as medical advice or a substitute for professional medical consultation, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide protocol.